Skip to main content

Advertisement

SpringerLink
Log in

Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and Management

  • SCLERODERMA (J VARGA, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Gastrointestinal (GI) involvement is frequent in scleroderma (systemic sclerosis [SSc]) and is the most frequent internal complication of the disease. Patients with GI involvement have impaired quality of life, and their prognosis may be one of severe impairment. Unfortunately, GI involvement is often noticed when severe complications have already occurred, is irreversible, and is difficult to manage. The past 2 to 3 years have been rich in exciting studies that we hope will help identify, prevent, treat, and monitor disease progression. Recent studies on the pathophysiology of GI tract disease could lead to advances in the treatment of GI tract involvement. The importance of treating gastroesophageal reflux (GER) has been reinforced by studies showing GER damage in almost all SSc patients, and the fact that GER damage is reversible if early treatment with proton pump inhibitors is introduced. Moreover, recent data showing a link between GER and interstitial lung disease in SSc underscore the importance of aggressive GER treatment in SSc patients. A novel lung pattern possibly related to GER also has been described. New, exciting data on gastric vascular antral ectasia have been published. Finally, malnutrition in SSc patients has been highlighted, and anorectal involvement has been emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ponge T, des Bruley SV. Atteintes digestives sclérodermiques. La Revue du Praticien. 2002;52:196–200.

    Google Scholar 

  2. Clements PJ, Becvar R, Drosos AA, et al. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21:S15–8.

    PubMed  CAS  Google Scholar 

  3. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437–44.

    Article  PubMed  CAS  Google Scholar 

  4. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37:1265–82.

    Article  PubMed  CAS  Google Scholar 

  5. Jaovisidha K, Csuka ME, Almagro UA, et al. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum. 2005;34:689–702.

    Article  PubMed  Google Scholar 

  6. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii36–9.

    Article  Google Scholar 

  7. Franck-Larsson K, Graf W, Rönnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study. Eur J Gastroenterol Hepatol. 2009;21:m176–82.

    Article  Google Scholar 

  8. Thombs BD, Hudson M, Taillefer SS, et al. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum. 2008;4:504–9.

    Article  Google Scholar 

  9. Attar A. Atteintes digestives au cours de la sclérodermie. Ann Med Interne (Paris). 2002;153:260–4.

    Google Scholar 

  10. Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma. A study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179:408–13.

    Article  PubMed  Google Scholar 

  11. Lock G, Holstege A, Lang B, et al. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92:763–71.

    PubMed  CAS  Google Scholar 

  12. Marie I, Lévesque H, Ducrotté P, et al. Atteinte de l’intestin grêle au cours de la sclérodermie systémique. Rev Med Interne. 1999;20:504–13.

    Article  PubMed  CAS  Google Scholar 

  13. D’Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–40.

    Article  PubMed  Google Scholar 

  14. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996;8:569–75.

    Article  PubMed  CAS  Google Scholar 

  15. Hendel L, Kobayasi T, Petri M. Ultrastructure of the small intestinal mucosa in progressive systemic sclerosis (PSS). Acta Pathol Microbiol Immunol Scand A. 1987;95:41–6.

    PubMed  CAS  Google Scholar 

  16. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:134–44.

    Article  PubMed  Google Scholar 

  17. Hendel L, Ammitzboll T, Dirksen K, Petri M, et al. Collagen components in the duodenal and rectal mucosa in progressive systemic sclerosis and other diseases. Acta Derm Venereol. 1986;66:220–4.

    PubMed  CAS  Google Scholar 

  18. Treacy WL, Baggenstoss AH, Slocumb CH, et al. Scleroderma of the esophagus. A correlation of histologic and physiologic findings. Ann Intern Med. 1963;59:351–6.

    PubMed  CAS  Google Scholar 

  19. Howe S, Eaker EY, Sallustio JE, et al. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94:761–70.

    Article  PubMed  CAS  Google Scholar 

  20. Eaker EY, Kuldau JG, Verne GN, et al. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med. 1999;133:551–6.

    Article  PubMed  CAS  Google Scholar 

  21. • Kawaguchi Y, Nakamura Y, Matsumoyo I, et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis 2009, 68: 710–714. To clarify the pathogenesis of GI tract involvement in SSc, the occurrence of autoantibody for M3R was investigated in 14 SSc patients and 70 healthy controls. Anti-M3R antibody was found more frequently in patients with SSc, suggesting that M3R-mediated enteric cholinergic neurotransmission may provide a pathogenic mechanism for GI tract dysmotility in SSc.

    Article  PubMed  CAS  Google Scholar 

  22. •• Singh J, Mehendiratta V, Del Galdo F, et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2009, 297: 206–213. This study determined the effect of SSc IgGs on the muscarinic receptor activation by bethanecol in smooth muscle cells and smooth muscle strips from rat IAS. The results suggest that SSc GI dysmotility may be caused by autoantibodies that inhibit the muscarinic neurotransmission in smooth muscle cells of the GI tract, opening a door for possible treatment of GI SSc disease directed at the removal or neutralization of the antibodies.

    Google Scholar 

  23. Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008;42:5–12.

    Article  PubMed  Google Scholar 

  24. Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972;58:30–44.

    PubMed  CAS  Google Scholar 

  25. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2010 Aug 14. [Epub ahead of print].

  26. Hendel L, Hage E, Hendel J, et al. Omeprazole in the long-term treatment of severe gastro-esophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther. 1992;6:565–77.

    Article  PubMed  CAS  Google Scholar 

  27. Marie I, Ducrotte P, Denis P, et al. Oesophageal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24(11–12):1593–601.

    Article  PubMed  CAS  Google Scholar 

  28. Wipff J, Coriat R, Masciocchi M, et al. Outcome of Barrett’s oesophagus related to systemic sclerosis: a 3 year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology. 2011;50(8):1440–4.

    Article  PubMed  Google Scholar 

  29. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Resp Crit Care Med. 2000;161:646–64.

    Google Scholar 

  30. Raghu G, Freudenberg TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic fibrosis. Eur Respir J. 2006;27:136–42.

    Article  PubMed  CAS  Google Scholar 

  31. Appel 3rd JZ, Lee SM, Hartwig MG, et al. Characterization of the innate immune response to chronic aspiration in a novel rodent model. Respir Res. 2007;8:87.

    Article  PubMed  Google Scholar 

  32. •• Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma. A study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179: 408–413. In this prospective study, 40 patients with SSc underwent pulmonary HRCT scan and 24-hour impedance pH monitoring off PPI therapy. Patients with ILD on HRCT had more reflux episodes and more reflux reaching the proximal esophagus, suggesting a relationship between GER and ILD. Whether the development of ILD in patients with SSc can be prevented via reflux-reducing treatments needs to be investigated.

    Article  PubMed  Google Scholar 

  33. •• Christmann RB, Wells AU, Capelozi VL, et al. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010, 40:241–249. In this review, the authors summarize clinical, radiologic, histopathologic, and treatment aspects of GER in SSc-ILD. They describe the association of GER with SSc-ILD strongly supported by several studies. They recommend aggressive treatment for reflux in all patients with ILD, keeping in mind, however, that future studies need to be conducted to prove long-term benefit of GER treatment in ILD.

    Article  PubMed  Google Scholar 

  34. Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic fibrosis: a case series. Chest. 2006;129(3):794–800.

    Article  PubMed  Google Scholar 

  35. •• de Souza RBC, Borges CTL, Capelozzi VL, et al.: Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 2009, 77: 389–397. In this prospective study, 28 patients with SSc-ILD went for open lung biopsy. A total of 21% of the patients had an isolated CLF, a novel histologic pattern described in idiopathic interstitial pneumonia. This pattern was also found in 84% of the patients with a predominant NSIP. A high frequency of esophageal abnormality was observed in both groups of CLF and NSIP, suggesting that the CLF pattern could be associated with GER.

    Article  PubMed  Google Scholar 

  36. De Carvalho ME, Kairalla RA, Capelozzi VL, et al. Centrilobular fibrosis: a novel histologic pattern of idiopathic interstitial pneumonia. Pathol Res Pract. 2002;198:577–83.

    Article  PubMed  Google Scholar 

  37. Brumit M, Carter E. Pathologic quiz case: patient with systemic sclerosis and anemia. Arch Pathol Lab Med. 2002;126:375–6.

    PubMed  Google Scholar 

  38. Marie I, Ducrotte P, Antoinietti M, et al. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther. 2008;28:412–21.

    Article  PubMed  CAS  Google Scholar 

  39. • Ingraham KM, O’Brien MS, Shenn M, et al. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol 2010, 37:603–7. To date, general characteristics of patients with watermelon stomach have rarely been studied. In this retrospective study, it was found that GAVE was associated with early diffuse SSc, rapid skin progression, and anti-RNA pol III antibodies.

    Article  PubMed  Google Scholar 

  40. Sellinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion. 2008;77:131–7.

    Article  Google Scholar 

  41. Schulz SW, O’Brien M, Maqsood M, et al. Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J Rheumatol. 2009;36:1653–6.

    Article  PubMed  CAS  Google Scholar 

  42. Stratton RJ, King CL, Stroud MA, et al. ‘Malnutrition Universal Screening Tool’ predicts mortality and length of hospital stay in acutely ill elderly. Br J Nutr. 2006;95:325–30.

    Article  PubMed  CAS  Google Scholar 

  43. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group Database. J Rheumatol. 2009;36:2737–43.

    Article  PubMed  Google Scholar 

  44. • Krause L, O Becker M, Brueckner CS, et al. Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 2010, 69: 1951–1957. This study showed that 55.7% of SSc patients had malnutrition, that the best predictors of malnutrition were low predicted forced vital capacity and high-NT–pro-BNP, and that malnutrition was associated with disease activity and severity. Also, severe malnutrition was a predictor of SSc-related mortality.

    Article  PubMed  Google Scholar 

  45. Jaffrin MY. Body composition determination by bioimpedance: an update. Curr Opin Clin Nutr Metab Care. 2009;12:482–6.

    Article  PubMed  Google Scholar 

  46. •• Baron M, Bernier P, Côté L-F, et al. Screening and management for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol 2010, 28 (Suppl. 58): 42–46. This article is the result of a meeting between experts in areas of nutrition, speech pathology, oral health in SSc, and SSc and gastroenterology. Recommendations regarding screening of malnutrition, evaluation, interventions, and follow-up were made.

    Google Scholar 

  47. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum. 2009;61:1257–63.

    Article  PubMed  Google Scholar 

  48. Perlemuter G, Cacoub P, Chaussade S, et al. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. 1999;42:545–9.

    Article  Google Scholar 

  49. Khanna D. Gastrointestinal involvement in systemic sclerosis. In: Font J, Ramos-Casals M, Rodés J, eds. Digestive Involvement in Systemic Autoimmune Diseases. New York: Elsevier:51–61.

  50. Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13:119–23.

    Article  PubMed  Google Scholar 

  51. Verne GN, Eaker EY, Hardy E, et al. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40:1892–901.

    Article  PubMed  CAS  Google Scholar 

  52. Brown M, Teubner A, Shaffer J, et al. Home parenteral nutrition—an effective and safe long-term therapy for systemic sclerosis-related intestinal failure. Rheumatology (Oxford). 2008;47:176–9.

    Article  CAS  Google Scholar 

  53. Mawdsley AH. Patient perception of UK scleroderma services—results of an anonymous questionnaire. Rheumatology. 2006;45:1573.

    Article  PubMed  CAS  Google Scholar 

  54. Engel AF, Kamm MA, Talbot IC. Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut. 1994;35:857–9.

    Article  PubMed  CAS  Google Scholar 

  55. Thoua NM, Schizas A, Forbes A, et al. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford). 2011 Apr 18. [Epub ahead of print].

  56. Roberts CG, Hummers LK, Ravich WJ, et al. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55:1697–703.

    Article  PubMed  CAS  Google Scholar 

  57. Thoua NM, Abdel-Halim M, Denton C, et al. Faecal incontinence in systemic sclerosis is related to sphincter atrophy and reflex dysfunction. Gut. 2009;58:A90.

    Article  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Jewish General Hospital, McGill University, Suite A 725, 3755 Cote Street, Catherine Road, Montreal, QC, H3T 1E2, Canada

    Genevieve Gyger & Murray Baron

Authors
  1. Genevieve Gyger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murray Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murray Baron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gyger, G., Baron, M. Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and Management. Curr Rheumatol Rep 14, 22–29 (2012). https://doi.org/10.1007/s11926-011-0217-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0217-3

Keywords

Search

Navigation